Abstract:Purpose:The purpose of this study was to establish a model for predicting early recurrence (≤2 years) of hepatocellular carcinoma (HCC) after anatomical hepatectomy based on the hepatobiliary phase (HBP) imaging characteristics of gadobenate-enhanced MRI.Methods:A total of 155 patients who underwent anatomical hepatectomy HCC therapy and gadobenate-enhanced MRI were included retrospectively. The patients were divided into the early recurrence-free group (n = 103) and the early recurrence group (n = 52). Univariate and multivariate Cox regression analysis was used to determine the independent risk factors related to early recurrence, and four models were established. The preoperative model with/without HBP imaging features (HBP-pre/No HBP-pre model) and the postoperative model with/without HBP imaging features (HBP-post/No HBP-post model). Bootstrap resampling 1,000 times was used to verify the model and displayed by nomograms. The performance of nomograms was evaluated by discrimination, calibration, and clinical utility. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were used to evaluate the differences between models and to select the optimal model.Results:Shape, arterial peritumoral enhancement, AFP-L3, and peritumoral hypointensity on HBP were identified as independent risk factors. Prothrombin time (PT) and r-glutamyltransferase (GGT) were selected by multivariate Cox regression. These six factors construct the HBP-pre model. Removing peritumoral hypointensity on HBP was the No HBP-pre model. Adding microvascular invasion (MVI) and microscopic capsule factors were the HBP-post and No HBP-post model. The C-index was 0.766, 0.738, 0.770, and 0.742, respectively. The NRI and IDI of the HBP-pre vs. the No HBP-pre model and the HBP-post vs. the No HBP-post model significantly increased 0.258, 0.092, 0.280, and 0.086, respectively. The calibration curve and decision curve analysis (DCA) had good consistency and clinical utility. However, the NRI and IDI of the No HBP-post vs. the No HBP-pre model and the HBP-post vs. the HBP-pre model did not increase significantly.Conclusions:Preoperative gadobenate-enhanced MR HBP imaging features significantly improve the model performance while the postoperative pathological factors do not. Therefore, the HBP-pre model is selected as the optimal model. The strong performance of this model may help hepatologists to assess the risk of recurrence in order to guide the selection of treatment options.

Hepatobiliary Phase Images of Gadoxetic Acid-Enhanced MRI May Improve Accuracy of Predicting the Size of Hepatocellular Carcinoma at Pathology

Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging Outperformed Multidetector Computed Tomography in Diagnosing Small Hepatocellular Carcinoma: A Meta-Analysis

Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis.

Comparison of Gd-EOB-DTPA-enhanced MRI and Contrast-enhanced Ultrasound for Measuring Tumor Size of Solitary Hepatocellular Carcinoma ≤ 5cm: A Real-World Study

Diagnostic Performance of Gadoxetic Acid-Enhanced Abbreviated Magnetic Resonance Imaging Protocol in Small Hepatocellular Carcinoma (≤2 Cm) in High-Risk Patients.

Is Liver-Specific Gadoxetic Acid-Enhanced Magnetic Resonance Imaging a Reliable Tool for Detection of Hepatocellular Carcinoma in Patients with Chronic Liver Disease?

Is Gadoxetic Acid Disodium (Gd-EOB-DTPA)-Enhanced Magnetic Resonance Imaging an Accurate Diagnostic Method for Hepatocellular Carcinoma? A Systematic Review with Meta-Analysis

Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging For The Detection Of Hepatocellular Carcinoma: A Meta-Analysis

A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MRI May Improve the Diagnostic Performance for Hepatocellular Carcinoma

Detection of Small Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced MRI: is the Addition of Diffusion-Weighted MRI at 3.0T Beneficial?

Gadoxetic Acid Disodium (Gd-Eobdtpa)-enhanced Magnetic Resonance Imaging for the Detection of Hepatocellular Carcinoma: a Meta-Analysis.

New Diagnosis Criteria for Hepatocellular Carcinoma: Gadoxetic Acid-enhanced MRI Integrating CT-Vascular Features May Facilitate Evaluation

Hepatobiliary Phase Features of Preoperative Gadobenate-Enhanced MR Can Predict Early Recurrence of Hepatocellular Carcinoma in Patients Who Underwent Anatomical Hepatectomy.

Added value of Gd-EOB-DTPA-enhanced Hepatobiliary phase MR imaging in evaluation of focal solid hepatic lesions

Prediction of Histologic Differentiation Grade of Hepatocellular Carcinoma by Magnetic Resonance Imaging with Hepatospecific Contrast Agent

A Compared Study on Gd+-EOB-DTPA and Gd+-DTPA-enhanced MRI in Detection of Hepatocellular Carcinoma

Comparison of Gadoxetic Acid Versus Gadopentetate Dimeglumine for the Detection of Hepatocellular Carcinoma at 1.5 T Using the Liver Imaging Reporting and Data System (LI-RADS V.2017)

Using Arterial Phase Hyperenhancement on CT Instead of Gadoxetic Acid Arterial Phase Enhancement May Improve the Diagnostic Performance for Hepatocellular Carcinoma

MRI characterization of focal liver lesions in non-cirrhotic patients: assessment of added value of gadoxetic acid-enhanced hepatobiliary phase imaging

Detection of hepatocellular carcinoma in a population at risk: iodine-enhanced multidetector CT and/or gadoxetic acid-enhanced 3.0 T MRI

Hepatocellular carcinoma 20 mm or smaller in cirrhosis patients: early magnetic resonance enhancement by gadoxetic acid compared with gadopentetate dimeglumine